Detalles de la búsqueda
1.
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Int J Gynecol Cancer
; 33(9): 1458-1463, 2023 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37666539
Resultados
1 -
1
de 1
1
Próxima >
>>